Biotechnology

Filter

Current filters:

None

Popular Filters

1 to 25 of 2444 results

Astellas and Cytokinetics expand accord on skeletal muscle activators

26-12-2014

US biotech firm Cytokinetics and Japanese pharma major Astellas Pharma have amended their collaboration…

Astellas PharmaBiotechnologyCK-2127107CytokineticsLicensingResearch

Ariad co-opts Otsuka for Iclusig in Japan and other Asian countries

24-12-2014

US specialty pharma firm Ariad Pharmaceuticals has entered into an agreement for Japan’s Otsuka Pharmaceuticals…

Ariad PharmaceuticalsAsia-PacificBiotechnologyIclusigJapanLicensingOncologyOtsuka PharmaceuticalResearch

US health care predictions from Steven Burrill

24-12-2014

US politics will continue to be characterized by partisanship as the Republican majorities in the House…

BiosimilarsBiotechnologyHealthcarePoliticsRegulationUSA

Janssen partners with MacroGenics in up to $625 million deal

Janssen partners with MacroGenics in up to $625 million deal

23-12-2014

Shares of US biotech firm MacroGenics rocketed 11.7% to a 10-month high of $38.58 yesterday, on the news…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingMacroGenicsMergers & AcquisitionsMGD011Oncology

NICE opens consultation on Millennium’s Crohn’s drug Entyvio

23-12-2014

In draft guidance issued today, UK health costs watchdog the National Institute for Health and Care Excellence…

BiotechnologyEntyvioGastro-intestinalsMillennium PharmaceuticalsPricingRegulationTakeda PharmaceuticalUK

NewLink Genetic and Merck Ebola collaboration gets $30 million government award

23-12-2014

US biotech firm NewLink Genetics saw its shares gain 4.1% to $40.11 in morning trading on Monday, following…

Anti-viralsBiotechnologyFinancialMerck & CoNewLink GeneticsResearchTropical diseasesUSA

EpiVax links with Novozymes Biopharma to advance autoimmune diseases treatment

23-12-2014

Danish drugmaker Novozymes’ Veltis albumin-based half-life extension platform will help move Tregitope…

BiotechnologyImmunologicalsLicensingNovozymesResearchTregitopeVeltis

Stem cell sector offers investors high returns to rejuvenate their investment portfolios

Stem cell sector offers investors high returns to rejuvenate their investment portfolios

22-12-2014

Dr Husein K Salem, founder and chief executive of Precious Cells Group (PCG), one of the UK’s leading…

BiotechnologyFinancialMarkets & MarketingPrecious Cells GroupResearch

Sevion in antibody discovery accord with Johnson & Johnson Innovation and Janssen

22-12-2014

USA-based biopharma firm Sevion Therapeutics has entered into a collaboration agreement with CNA Development,…

BiotechnologyJanssenJohnson & JohnsonLicensingResearchSevion Therapeutics

Tiziana licenses anti-inflammatory foralumab from Novimmune

Tiziana licenses anti-inflammatory foralumab from Novimmune

22-12-2014

Oncology and immunology specialist Tiziana and antibody-based drug manufacturer Novimmune have entered…

BiotechnologyImmunologicalsLicensingNovImmuneTiziana

Roche shares fall sharply on disappointing Ph III MARIANNE study

Roche shares fall sharply on disappointing Ph III MARIANNE study

22-12-2014

Swiss pharma major Roche saw its shares plunge 6.4% to 270.40 Swiss francs on Friday following release…

BiotechnologyGenentechHerceptinKadcylaOncologyPerjetaRoche

Bina Technologies is acquired by Roche

20-12-2014

Swiss pharma giant Roche has acquired Bina Technologies, a privately held company based in Redwood City,…

Bina TechnologiesBiotechnologyMergers & AcquisitionsRoche

RXi and Hapten enter into licensing agreement for Samcyprone

RXi and Hapten enter into licensing agreement for Samcyprone

19-12-2014

RNA technology specialist RXi Pharmaceuticals Corp has entered into a global licensing agreement with…

BiotechnologyDermatologicalsLicensingNeurologicalRXi Pharmaceuticals

UPDATE: Lilly rekindles deal with Adocia to develop ultra rapid insulin

UPDATE: Lilly rekindles deal with Adocia to develop ultra rapid insulin

19-12-2014

US pharma major Eli Lilly and French biotech firm Adocia have entered into a worldwide licensing collaboration…

AdociaBioChaperone LisproBiotechnologyDiabetesEli LillyGlobalLicensing

Gilead and Ono enter into a licensing agreement for ONO-4059

Gilead and Ono enter into a licensing agreement for ONO-4059

19-12-2014

Japanese pharma company Ono Pharmaceutical and US biotech major Gilead Sciences have entered into a licensing…

BiotechnologyGilead SciencesLicensingOncologyOno PharmaceuticalONO-4059Research

Sorrento and Conkwest join forces on cancer immunotherapies development

Sorrento and Conkwest join forces on cancer immunotherapies development

19-12-2014

US cancer drug developer Sorrento Therapeutic and privately-held Conkwest have entered into a definitive…

BiotechnologyConkwestFinancialNeukoplastOncologyResearchSorrento Therapeutics

Merck & Co in up to $375 million deal to acquire OncoEthix

Merck & Co in up to $375 million deal to acquire OncoEthix

19-12-2014

US pharma giant Merck & Co said yesterday that it has acquired, through a subsidiary, Swiss-based privately…

BiotechnologyMerck & CoMergers & AcquisitionsOncoEthixOncologyOTX015

Roche to acquire Austrian next-generation antibody firm Dutalys

Roche to acquire Austrian next-generation antibody firm Dutalys

19-12-2014

Swiss pharma giant Roche has agreed to acquire Dutalys, a privately held biotechnology company based…

BiotechnologyDutalysDutaMabMergers & AcquisitionsOncologyRoche

France Biotech presents twelfth annual Panorama of the Life Sciences survey results

France Biotech presents twelfth annual Panorama of the Life Sciences survey results

18-12-2014

France Biotech, an association for life sciences entrepreneurs, has published the twelfth edition of…

BiotechnologyFrancePoliticsProductionResearch

Claritas Genomics appoints Patrick Terry as chief commercial officer

Claritas Genomics appoints Patrick Terry as chief commercial officer

18-12-2014

Genetic diagnostic lab, Claritas Genomics, has appointed Patrick Terry as chief commercial officer.

BiotechnologyBoardroomClaritas GenomicsGenomicsPatrick Terry

Amgen reveals Blincyto price as $178,000 per course

Amgen reveals Blincyto price as $178,000 per course

18-12-2014

USA-based Amgen has revealed its intended pricing for its immunotherapy Blincyto (blinatumomab), which…

AmgenBiotechnologyBlincytoOncologyPricingUSA

X-Chem licenses second cardiovascular drug discovery program to Bayer

X-Chem licenses second cardiovascular drug discovery program to Bayer

18-12-2014

Privately-held biotech firm X-Chem has licensed a second drug discovery program to German pharma major…

BayerBiotechnologyCardio-vascularLicensingX-Chem

1 to 25 of 2444 results

Back to top